BTIG analyst Ryan Zimmerman maintained a Buy rating on Vericel Corp (VCEL) yesterday and set a price target of $24. The company’s shares closed last Monday at $17.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 20.6% and a 60.7% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.
Vericel Corp has an analyst consensus of Moderate Buy, with a price target consensus of $24.
See today’s analyst top recommended stocks >>
Based on Vericel Corp’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $19.79 million. In comparison, last year the company had a GAAP net loss of $4.65 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio includes MACI and Epicel.